Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.

ABSTRACT:

Background

The effectiveness of glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in preventing major adverse cardiac events (MACE) is uncertain for those without preexisting cardiovascular disease.

Objective

To test the hypothesis that MACE incidence was lower with the addition of GLP1RA or SGLT2i compared with dipeptidyl peptidase-4 inhibitors (DPP4i) for primary cardiovascular prevention.

Design

Retrospective cohort study of U.S. veterans from 2001 to 2019.

Setting

Veterans aged 18 years or older receiving care from the Veterans Health Administration, with data linkage to Medicare, Medicaid, and the National Death Index.

Patients

Veterans adding GLP1RA, SGLT2i, or DPP4i onto metformin, sulfonylur

SUBMITTER: Richardson TL 

PROVIDER: S-EPMC10367222 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature